Table 3.
Baseline model: 478 seropositives vs. 799 seronegativesb | Interim model: 678 seropositives vs. 599 seronegatives-c | |||||
---|---|---|---|---|---|---|
Factorsa in model | OR | 95% CI | Adjusted P | OR | 95% CI | Adjusted P |
Age >40 years | 1.18 | 0.84–1.68 | 0.343 | 0.85 | 0.61–1.20 | 0.363 |
Female sex | 1.07 | 0.85–1.37 | 0.557 | 1.20 | 0.95–1.51 | 0.129 |
Country (Rwanda) | 3.50 | 1.27–9.62 | 0.015 | 1.18 | 0.44–3.13 | 0.742 |
rs12407485-A | 0.71 | 0.55–0.90 | 0.005d | 0.69 | 0.55–0.87 | 0.002d |
As defined in Table 1 and text. Odds ratio (OR) and confidence interval (CI) are further adjusted for genetic ancestry (MDS1-MDS4, see text). OR >1.0 is unfavorable (being seropositive).
At enrollment, only SPs (n = 478) are HIV-1 seropositive, while the other subjects (n = 799) are seronegative.
Up to two years of follow-up after enrollment, with 200 confirmed seroconversion events (as in Figure 3).
P ≥0.19 when corrected for 95 independent tests.